ATE495442T1 - Zusammensetzungen und verfahren zur erkennung von sirolimus - Google Patents

Zusammensetzungen und verfahren zur erkennung von sirolimus

Info

Publication number
ATE495442T1
ATE495442T1 AT06758774T AT06758774T ATE495442T1 AT E495442 T1 ATE495442 T1 AT E495442T1 AT 06758774 T AT06758774 T AT 06758774T AT 06758774 T AT06758774 T AT 06758774T AT E495442 T1 ATE495442 T1 AT E495442T1
Authority
AT
Austria
Prior art keywords
sirolimus
poly
amino acid
compounds
compound
Prior art date
Application number
AT06758774T
Other languages
English (en)
Inventor
Cathy Worley
Yali Yang
Yi-Feng Zheng
Hshiou-Ting Liu
Holger Keim
Jian Chen
Original Assignee
Siemens Healthcare Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics filed Critical Siemens Healthcare Diagnostics
Application granted granted Critical
Publication of ATE495442T1 publication Critical patent/ATE495442T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/13—Tracers or tags

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Ceramic Engineering (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06758774T 2005-04-27 2006-04-27 Zusammensetzungen und verfahren zur erkennung von sirolimus ATE495442T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/116,928 US7189582B2 (en) 2005-04-27 2005-04-27 Compositions and methods for detection of sirolimus
PCT/US2006/016408 WO2006116727A2 (en) 2005-04-27 2006-04-27 Compositions and methods for detection of sirolimus

Publications (1)

Publication Number Publication Date
ATE495442T1 true ATE495442T1 (de) 2011-01-15

Family

ID=37215578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06758774T ATE495442T1 (de) 2005-04-27 2006-04-27 Zusammensetzungen und verfahren zur erkennung von sirolimus

Country Status (6)

Country Link
US (1) US7189582B2 (de)
EP (1) EP1880215B1 (de)
AT (1) ATE495442T1 (de)
DE (1) DE602006019575D1 (de)
ES (1) ES2358530T3 (de)
WO (1) WO2006116727A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106874A2 (en) * 2006-03-14 2007-09-20 Autocraft Industries, Inc. Improved wheelchair
US7883855B2 (en) * 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
EP2118656B1 (de) * 2006-12-29 2012-08-29 Abbott Laboratories Verbessertes testverfahren für immunsuppressiva
US7914999B2 (en) * 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
WO2008082984A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
ES2405364T3 (es) 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
US7910378B2 (en) * 2007-12-14 2011-03-22 Siemens Healthcare Diagnostics Inc. Methods for detection of hydrophobic drugs
US20090170218A1 (en) * 2008-01-02 2009-07-02 Dade Behring Inc. Methods for detection of cyclosporin a
US7842475B2 (en) * 2008-01-08 2010-11-30 Siemens Healthcare Diagnostics Inc. Stabilization of solid support assay reagents
US20120237550A1 (en) * 2011-03-16 2012-09-20 Siemens Healthcare Diagnostics Inc. Maintaining Antibody-Binding Activity Of Immunosuppressant Drug Conjugates
US9658218B2 (en) * 2012-05-07 2017-05-23 Siemens Healthcare Diagnostics Inc. Determination of total analyte concentration
WO2016100116A1 (en) * 2014-12-17 2016-06-23 Siemens Healthcare Diagnostics Inc. Sandwich assay design for small molecules
US20180306828A1 (en) * 2015-10-29 2018-10-25 Siemens Healthcare Diagnostics Inc. Sandwich assay for small molecules
IL312291A (en) * 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
MX2020011565A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
CN110736836B (zh) * 2018-07-19 2023-08-18 上海云泽生物科技有限公司 一种高灵敏度胶乳增强免疫比浊法测定全血中免疫抑制剂他克莫司的试剂盒
ES2992864T3 (en) * 2018-11-02 2024-12-18 Siemens Healthcare Diagnostics Inc Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof
CN110174363A (zh) * 2019-01-09 2019-08-27 北京九强生物技术股份有限公司 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途
CN112011516A (zh) * 2020-09-01 2020-12-01 江南大学 一株西罗莫司单克隆抗体杂交瘤细胞株及其应用
CA3256390A1 (en) 2022-05-25 2023-11-30 Revolution Medicines, Inc. CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
KR20250081554A (ko) * 2023-11-29 2025-06-05 주식회사 에스엔바이오사이언스 시롤리무스 및 알부민을 포함하는 나노입자, 이를 포함하는 피하투여용 약제학적 조성물 및 이의 제조방법

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153447A (en) * 1971-04-27 1979-05-08 Schering Aktiengesellschaft Herbicidal methylphenyl carbamates
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4220722A (en) 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US5169773A (en) * 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
US4661408A (en) 1986-03-18 1987-04-28 E.I. Du Pont De Nemours And Company Coated chromium dioxide particles
US4883751A (en) * 1986-05-28 1989-11-28 New York University Specific immunoassay for heparin
US4769165A (en) 1987-01-20 1988-09-06 E. I. Du Pont De Nemours And Company Process for synthesis of ferromagnetic chromium dioxide
US5089390A (en) 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US5233025A (en) * 1988-09-02 1993-08-03 Matsushita Electric Industrial Co., Ltd. Amphetamine protein complex as immunogen for obtaining antibodies specific to methamphetamine
US4920218A (en) * 1988-10-12 1990-04-24 Merck & Co., Inc. Novel hydroxide mediated FK-506 rearrangement process
CA1316916C (en) 1988-10-12 1993-04-27 David Askin Hydroxide mediated fk-506 rearrangement product
US5698448A (en) * 1988-12-02 1997-12-16 Soldin; Steven J. Immunosuppressive drug binding proteins and use
US5135863A (en) 1988-12-23 1992-08-04 Syntex (U.S.A.) Inc. Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine
US5508178A (en) 1989-01-19 1996-04-16 Rose; Samuel Nucleic acid amplification using single primer
AU648022B2 (en) * 1989-03-14 1994-04-14 Bionebraska, Inc. Monoclonal antibodies for metallic cations on small molecules
US5101015A (en) 1989-04-10 1992-03-31 Abbott Laboratories Reagents for an amphetamine-class fluorescence polarization immunoassay
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5283190A (en) * 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
WO1991010907A1 (en) 1990-01-22 1991-07-25 Synbiotics Corporation Pharmacologically active compound screening antibodies and hierarchical cluster analysis
US5164299A (en) 1990-03-20 1992-11-17 E. I. Du Pont De Nemours And Company Use of a mixture of conjugated and unconjugated solid phase binding reagent to enhance the performance of assays
US5120726A (en) * 1991-03-08 1992-06-09 American Home Products Corporation Rapamycin hydrazones
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
DE69133095T2 (de) * 1990-11-20 2003-03-27 Dade Behring Marburg Gmbh Cyclosporin-Immunoassay
US5656434A (en) * 1990-12-28 1997-08-12 Suntory Limited Monoclonal antibody against cardiac glycoside and utilization thereof
NO921449L (no) 1991-04-17 1992-10-19 American Home Prod Karbamater av rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
AU2007192A (en) 1991-05-08 1992-12-21 Vertex Pharmaceuticals Incorporated Rfkbp: a novel prolyl isomerase and rapamycin/fk506 binding protein
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US5120725A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
CA2102116A1 (en) * 1991-05-31 1992-12-01 Gary R. Schulte Use of rapamycin prodrugs as immunosuppressant agents
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5498597A (en) * 1992-01-17 1996-03-12 Dana-Farber Cancer Institute, Inc. FKBP-13, an FK506-binding immunophilin
WO1993025533A1 (en) * 1992-06-05 1993-12-23 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
ZA935111B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935110B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) * 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
SG47580A1 (en) 1992-10-13 1998-04-17 American Home Prod Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
US6455288B1 (en) 1993-04-08 2002-09-24 Dade Behring Marburg Gmbh Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases
US5354845A (en) * 1993-04-21 1994-10-11 Children's Research Institute FK-506 and rapamycin specific binding immunophilin
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
WO1994025072A1 (en) 1993-04-23 1994-11-10 American Home Products Corporation Rapamycin conjugates and antibodies
ES2295093T3 (es) 1993-04-23 2008-04-16 Wyeth Conjugados y anticuerpos de rapamicina.
USRE37421E1 (en) * 1993-07-16 2001-10-23 Smithkline Beecham Corporation Rapamycin derivatives
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
SK78196A3 (en) * 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5525610A (en) 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5985890A (en) * 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
PT956034E (pt) * 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US6709873B1 (en) * 1997-04-09 2004-03-23 Isodiagnostika Inc. Method for production of antibodies to specific sites of rapamycin
CA2286311A1 (en) 1997-04-09 1998-10-15 Isotechnika, Inc. Method for production of antibodies to specific sites of rapamycin
US6231982B1 (en) 1997-12-10 2001-05-15 Dade Behring Inc. Particle reagents having reduced matrix effects and containing an aldehyde-reactive functional group
DK1419154T3 (da) * 2001-08-22 2006-01-09 Wyeth Corp Rapamycin-29-enoler
WO2005088307A1 (en) * 2004-03-10 2005-09-22 Seradyn Inc. Immunoassays for everolimus

Also Published As

Publication number Publication date
ES2358530T3 (es) 2011-05-11
EP1880215B1 (de) 2011-01-12
EP1880215A2 (de) 2008-01-23
WO2006116727A3 (en) 2007-03-08
DE602006019575D1 (de) 2011-02-24
WO2006116727A2 (en) 2006-11-02
US20060246518A1 (en) 2006-11-02
EP1880215A4 (de) 2008-05-14
US7189582B2 (en) 2007-03-13

Similar Documents

Publication Publication Date Title
ATE495442T1 (de) Zusammensetzungen und verfahren zur erkennung von sirolimus
WO2004072235A3 (en) Cotton event mon 88913 and compositions and methods for detection thereof
WO2004053062A3 (en) Bentgrass event asr-368 and compositions and methods for detection thereof
GB0617429D0 (en) Markers of renal transplant rejection and renal damage
WO2005059103A3 (en) Corn plant mon88017 and compositions and methods for detection thereof
BR0212968A (pt) Composição farmacêutica, composto, e, método para tratar ou prevenir condições mediadas pelo ccr2, mcp-1 ou pela interação destes
EP2248869A3 (de) Verbindungen für organische elektronische Vorrichtungen
DE602004011105D1 (de) Verfahren, peptide und biosensoren mit eignung zum nachweis eines breiten spektrums von bakterien
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
CY1116208T1 (el) Υδατο-διαλυτη ενωση βενζοαζεπινης και η φαρμακευτικη συνθεση αυτης
DE60123933D1 (de) Fluoreszierende proben zur quantitativen bestimmung von zink
DE60025744D1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
WO2007035864A3 (en) Electrophoresis standards, methods and kits
WO2008020823A3 (en) Cooperative reporter systems, components, and methods for analyte detection
NO20060125L (no) Sammensetning og fremgangsmate for avledningsmidler for syrestimulering av undergrunns formasjoner
BRPI0607323A2 (pt) composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE50012832D1 (de) Halbleiterbauelement, elektronisches bauteil, sensorsystem und verfahren zur herstellung eines halbleiterbauelementes
GB2428042A (en) P gingivalis vaccine
WO2004022769A3 (fr) Moyens de detection des processus neurodegeneratifs et leurs applications
EP1310490A4 (de) Gpr14-antagonisten
EP1312673A4 (de) Verfahren zum schutz von persönlicher information
EA200701578A1 (ru) Способ конъюгирования молекул, содержащих аминотиол, к носителям
BRPI0601766A (pt) composições contendo aminas e seu uso
EP2489734A4 (de) Nukleinsäuremolekül mit affinität mit igg-antikörper aus nager, bindemittel, nachweisreagens und nachweiskit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties